Citi raised the firm’s price target on Medline (MDLN) to $60 from $48 and keeps a Buy rating on the shares. The firm sees a “compelling” setup for the shares post the Q4 beat. It updated Medline’s model following the “clean” quarter.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN: